Sarepta’s Next-Gen DMD Drug SRP-5051 Shows Advantages, But Safety Concerns Too

 
• By Alaric DeArment
  
MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
Sarepta announced data on four patients from the first part of its Phase II trial of SRP-5051 • Source: Shutterstock

More from Rare Diseases

More from Scrip